![](/img/cover-not-exists.png)
Multi-center, randomized, double-blind, placebo-controlled, exploratory study to evaluate the efficacy and safety of HAD-B1 for dose-finding in EGFR positive and locally advanced or metastatic NSCLC subjects who need Afatinib therapy
Park, So-Jung, Kang, Hwi-Joong, Jun, Hyung-Joon, Shin, Seong-Hoon, Yoo, Hwa-SeungVolume:
99
Journal:
Medicine
DOI:
10.1097/MD.0000000000018735
Date:
January, 2020
File:
PDF, 300 KB
2020